|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 10/30/19 Ekso Bionics Holdings, Inc. 10-Q 9/30/19 84:7.7M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 622K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
61: R1 Document And Entity Information HTML 50K
19: R2 Condensed Consolidated Balance Sheets HTML 115K
43: R3 Condensed Consolidated Balance Sheets HTML 46K
(Parenthetical)
75: R4 Condensed Consolidated Statements of Operations HTML 94K
and Comprehensive Income (Loss)
62: R5 Consolidated Statements of Stockholders' Equity HTML 102K
20: R6 Condensed Consolidated Statements of Cash Flows HTML 123K
44: R7 Organization HTML 40K
73: R8 Basis of Presentation and Summary of Significant HTML 72K
Accounting Policies and Estimates
65: R9 Accumulated Other Comprehensive Income (Loss) HTML 30K
26: R10 Fair Value Measurements HTML 73K
32: R11 Inventories, net HTML 33K
77: R12 Revenue Recognition HTML 124K
48: R13 Investment in Unconsolidated Affiliate HTML 38K
25: R14 Accrued Liabilities HTML 54K
31: R15 Long-Term Debt HTML 64K
76: R16 Lease Obligations HTML 48K
47: R17 Capitalization and Equity Structure HTML 97K
24: R18 Stock-based Compensation HTML 97K
33: R19 Income Taxes HTML 26K
72: R20 Commitments and Contingencies HTML 32K
64: R21 Net Income (Loss) Per Share HTML 69K
18: R22 Segment Disclosures HTML 98K
46: R23 Related Party Transactions HTML 28K
71: R24 Subsequent Events HTML 28K
63: R25 Basis of Presentation and Summary of Significant HTML 105K
Accounting Policies and Estimates (Policies)
17: R26 Accumulated Other Comprehensive Income (Loss) HTML 29K
(Tables)
45: R27 Fair Value Measurements (Tables) HTML 71K
74: R28 Inventories, net (Tables) HTML 35K
60: R29 Revenue Recognition (Tables) HTML 115K
49: R30 Accrued Liabilities (Tables) HTML 55K
80: R31 Long-Term Debt (Tables) HTML 57K
29: R32 Lease Obligations (Tables) HTML 40K
22: R33 Capitalization and Equity Structure (Tables) HTML 77K
50: R34 Stock-based Compensation (Tables) HTML 99K
81: R35 Net Income (Loss) Per Share (Tables) HTML 72K
30: R36 Segment Disclosures (Tables) HTML 100K
23: R37 Organization (Details) HTML 56K
51: R38 Basis of Presentation and Summary of Significant HTML 55K
Accounting Policies and Estimates (Details)
78: R39 Accumulated Other Comprehensive Income (Loss) HTML 35K
(Details)
55: R40 Fair Value Measurements - Fair Value Hierarchies HTML 38K
(Details)
67: R41 Fair Value Measurements - Change in Level 3 HTML 43K
(Details)
40: R42 Inventories, net (Details) HTML 33K
15: R43 Revenue Recognition - Deferred Revenue (Details) HTML 41K
56: R44 Revenue Recognition - Deferred Revenue Activity HTML 30K
(Details)
68: R45 Revenue Recognition - Additional Information HTML 41K
(Details)
41: R46 Revenue Recognition - Performance Obligations HTML 37K
(Details)
16: R47 Revenue Recognition - Disaggregation of Revenue HTML 61K
(Details)
57: R48 Investment in Unconsolidated Affiliate - Narrative HTML 63K
(Details)
66: R49 Investment in Unconsolidated Affiliate - HTML 37K
Additional Information (Details)
83: R50 Accrued Liabilities - Schedule of Accrued HTML 41K
Liabilities (Details)
54: R51 Accrued Liabilities - Product Maintenance and HTML 30K
Warranty (Details)
28: R52 Long-Term Debt - Additional Information (Details) HTML 57K
36: R53 Long-Term Debt - Debt Repayment (Details) HTML 47K
82: R54 Long-Term Debt - Interest Debt Expense (Details) HTML 36K
53: R55 Lease Obligations - Additional Information HTML 36K
(Details)
27: R56 Lease Obligations - Future Minimum Payments HTML 48K
(Details)
35: R57 Capitalization and Equity Structure - Additional HTML 113K
Information (Details)
84: R58 Capitalization and Equity Structure - Warrants HTML 68K
(Details)
52: R59 Capitalization and Equity Structure - Valuation HTML 50K
Assumptions (Details)
14: R60 Stock-based Compensation - Additional Information HTML 52K
(Details)
38: R61 Stock-based Compensation - Stock Option Activity HTML 80K
(Details)
70: R62 Stock-based Compensation - Valuation Assumptions HTML 45K
(Details)
59: R63 Stock-based Compensation - RSU Activity (Details) HTML 44K
13: R64 Stock-based Compensation - Compensation Expense HTML 35K
(Details)
37: R65 Commitments and Contingencies (Details) HTML 39K
69: R66 Net Income (Loss) Per Share - Earnings Per Share HTML 50K
(Details)
58: R67 Net Income (Loss) Per Share - Antidilutive Shares HTML 35K
(Details)
12: R68 Segment Disclosures - Operating Segments (Details) HTML 46K
39: R69 Segment Disclosures - Geographical Segments HTML 31K
(Details)
34: R70 Related Party Transactions (Details) HTML 30K
79: XML IDEA XML File -- Filing Summary XML 151K
42: EXCEL IDEA Workbook of Financial Reports XLSX 94K
6: EX-101.INS XBRL Instance -- ekso-20190930 XML 2.42M
8: EX-101.CAL XBRL Calculations -- ekso-20190930_cal XML 213K
9: EX-101.DEF XBRL Definitions -- ekso-20190930_def XML 615K
10: EX-101.LAB XBRL Labels -- ekso-20190930_lab XML 1.61M
11: EX-101.PRE XBRL Presentations -- ekso-20190930_pre XML 970K
7: EX-101.SCH XBRL Schema -- ekso-20190930 XSD 170K
21: ZIP XBRL Zipped Folder -- 0001549084-19-000007-xbrl Zip 230K
| Exhibit |
(1) | I have reviewed this Quarterly Report on Form 10-Q of Ekso Bionics Holdings, Inc.; |
(2) | Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
(3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; |
(4) | The
company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the
company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the company’s internal
control over financial reporting; and |
(5) | The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions): |
(a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting. |
/s/ John F. Glenn | |
Principal Financial Officer | |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 10/30/19 | 8-K | ||
| For Period end: | 9/30/19 | |||
| List all Filings | ||||